Mijail Ivan Zambrano Iglesias

Dr. Mijail Ivan Zambrano Iglesias

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FMFedor Wadi Richani Meinhardt
Fedor Wadi Richani Meinhardt
MIMijail Ivan Zambrano Iglesias
Mijail Ivan Zambrano Iglesias
Maria Paula Fernandez GomezMaria Paula Fernandez Gomez
Maria Paula Fernandez Gomez
JFJesus Francisco Saltaren Fonseca
Jesus Francisco Saltaren Fonseca
Atif HusseinAtif Hussein
Atif Hussein
LRLuis E Raez
Luis E Raez
This review discusses the role of human epidermal growth factor receptor 2 (HER2/ERBB2) as a key oncogenic driver in non-small cell lung cancer (NSCLC), including exon 20 activating mutations, gene amplification, and protein overexpression. These forms differ in their biological effects and predictive value, but HER2 mutations, especially exon 20 insertions, are the primary oncogenic mechanism. Regarding diagnosis, Next-Generation Sequencing (NGS) is used to identify mutations, whereas Immunohistochemistry (IHC) and in situ hybridization are used to assess HER2 expression. Concerning treatment, in advanced HER2-positive, Non-Squamous NSCLC tumors, the first-line treatment is Platinum-based + Pemetrexed chemotherapy, with or without immunotherapy, because no HER2-targeted antibody therapy has yet been approved for initial treatment. After progression, HER2-targeted antibody-drug conjugates like Trastuzumab-Deruxtecan and Ado Trastuzumab-Emtansine may offer patients clinical benefits. New HER2-selective tyrosine kinase inhibitors, such as zongertinib and sevabertinib, have shown promising results, including patients previously treated with antibody–drug conjugates (ADCs). Recent advances, including next-generation ADCs such as SHR-A1811 and A166, and bispecific antibodies, such as zenocutuzumab for NRG1 fusion–positive disease, which are also expanding treatment options. Overall, advances in diagnostics and new targeted therapies are changing how HER2-altered NSCLC is treated and are helping to make care more personalized.

7 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MIMijail Ivan Zambrano Iglesias
Mijail Ivan Zambrano Iglesias
DRDaniel Rosas
Daniel Rosas
SASalih Akgun
Salih Akgun
ICInes Cristina Padron Cubillan
Ines Cristina Padron Cubillan
FMFedor Wadi Richani Meinhardt
Fedor Wadi Richani Meinhardt
LRLuis E Raez
Luis E Raez
Small cell lung cancer (SCLC) has historically been treated as a single, uniformly aggressive disease defined by neuroendocrine differentiation, near-universal loss of TP53 and RB1, and the absence of classical druggable oncogene addictions. Two converging lines of evidence are now reshaping that view. First, transcriptomic profiling has resolved SCLC into molecular subtypes—SCLC-A (ASCL1-driven), SCLC-N (NEUROD1-driven), SCLC-P (POU2F3-driven), and SCLC-I (inflamed)—with distinct immune microenvironments, surface-antigen expression patterns, and emerging therapeutic vulnerabilities, although intratumoral heterogeneity and phenotypic plasticity complicate clean subtype assignment. Second, the development of delta-like ligand 3 (DLL3)-directed therapies provides a natural experiment: the same validated surface antigen failed as an antibody–drug conjugate (rovalpituzumab tesirine, three negative randomized trials) yet succeeded as a bispecific T-cell engager (tarlatamab, which received FDA accelerated approval in 2024 and subsequent traditional FDA approval in 2025 following positive confirmatory phase 3 data). In this review, we integrate the current first-line standard of care—chemoimmunotherapy with atezolizumab- or durvalumab-based regimens followed by maintenance intensification with lurbinectedin–atezolizumab (IMforte)—with the molecular framework of subtypes and biomarkers, and we use DLL3 as a case study to propose that delivery modality is an important determinant of therapeutic success in SCLC and should be considered alongside target biology and tumor heterogeneity. Rapid proliferation, antigen heterogeneity, subtype plasticity, and a relatively less immunogenic microenvironment systematically penalize modalities dependent on payload accumulation and cell-cycle progression and reward modalities that recruit catalytic, cell-cycle-independent cytotoxic effectors. The emerging B7-H3 and SEZ6 programs—including ifinatamab deruxtecan and ABBV-706—are the next test of this framework. We discuss implications for biomarker development, trial design, and the operational challenges of subtype-guided precision oncology in a disease where tissue is scarce and biology shifts under therapy.